Fig. 1 · Structure

Documents & Downloads

Torin 2

Cat. No. A11586 CAS 1223001-51-1

mTOR inhibitor

Torin 2 is a potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively).

In Stock

Publications for Torin 2

1 publication citing this product

  1. Diane Yang, .et al. , Diabetes, 2021, Oct;70(10):2419-2429 PMID: 34344789

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Torin 2 acts as an ATP-competitive mTOR inhibitor. In an isolated human mTORC1 assay, increasing ATP shifted the Torin2 concentration required for inhibition upward. This supports competition with ATP; the assay does not establish a clinical dose. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
mTOR (p53?/? MEFs) 0.25 nM
ATM (PC3 cells) EC50 28 nM
ATR (PC3 cells) EC50 35 nM
DNA-PK (PC3 cells) EC50 118 nM

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 GI50 32.19 nM Growth inhibition of human HCT116 cells measured after 72 hrs by Celltiter-Glo assay [PMID: 32911078]
HeLa IC50 < 10 nM Inhibition of N-terminally FLAG-tagged mTORC2 (unknown origin) expressed in human HeLa cells using S6K1 or Akt1 as substrate after 20 mins by immunoblotting assay [PMID: 29211480]
HeLa GI50 97.95 nM Growth inhibition of human HeLa cells measured after 72 hrs by Celltiter-Glo assay [PMID: 32911078]
MOLM-13 IC50 < 1 nM Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay [PMID: 30370766]
MOLM-14 IC50 < 1 nM Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay [PMID: 30370766]
MV4-11 IC50 < 1 nM Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay [PMID: 30370766]
PC-3 EC50 200 nM Inhibition of PI3Kalpha in human PC3 cells expressing Akt1 S473D mutant assessed as phosphorylation of Akt Thr308 by immunoblotting [PMID: 21322566]
RD CC50 0.04 μM Cytotoxicity against human RD cells incubated for 4 days by CellTiter-Glo luminescence assay [PMID: 31082764]

In Vitro Studies

Torin 2 also inhibits cellular DNA-damage signaling through ATM, ATR and DNA-PK. In HCT-116 immunoblot assays, reported pathway EC50 values were 28, 35 and 118 nM, respectively. These cellular endpoints caution against attributing every Torin2 response exclusively to mTOR. [1]

ATP competition at mTORC1

Biochemical assay · Isolated human mTORC1 complex with GFP–4E-BP1 substrate [1]

Torin2 IC50 increased as ATP concentration increased, supporting ATP-competitive inhibition of mTORC1. The plot is used for direction only; no exact IC50 is estimated from its points.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mTORC1-mediated 4E-BP1 phosphorylationATP dependence IC50 increased with increasing ATP[1]

Literature-Reported Treatment Conditions

Treatment concentration
Threefold serial inhibitor dilution, 10 points; IC50 tested over a range of ATP concentrations
Exposure duration
30 min preincubation; 90 min kinase reaction
Method
Lanthascreen time-resolved FRET readout of 4E-BP1 Thr46 phosphorylation
Reported limits
Exact inhibitor concentrations and ATP series are not enumerated in the adopted text; no numeric potency is inferred from Fig. 1B. Vehicle is not specified for this assay.
Methods and source locations

Compound reported in the paper: Torin 2; Compound label in the paper: Torin2

Evidence concerns the reported experimental Torin2 material; supplier or lot equivalence is not established.

Materials and Methods: ATP competition assay; Results: Torin2 is a potent and selective ATP-competitive mTOR inhibitor in vitro; Fig. 1A,B

mTORC1-mediated 4E-BP1 phosphorylation: Time-resolved FRET; each point duplicated; IC50 values calculated in Prism4 — ATP competition assay; Fig. 1B and first Results subsection

Cellular inhibition of ATM, ATR and DNA-PK signaling

Cell-based study · HCT-116 cells subjected to DNA-damage stimulation [1]

Torin2 inhibited phosphorylation readouts for ATM, ATR and DNA-PK in cells. These pathway EC50 values show that the compound is not restricted to mTOR at higher cellular concentrations; they are not direct enzyme IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATM pathway: Chk2 phosphorylationCellular EC50 28 nM[1]
ATR pathway: Chk1 Ser317 phosphorylationCellular EC50 35 nM[1]
DNA-PK Ser2056 phosphorylationCellular EC50 118 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Torin2 concentration series; endpoint EC50 values are reported below
Exposure duration
1 h pretreatment; lysates collected 1 h after DNA-damage stimulation
Method
Immunoblotting after UV stimulation for ATR or ionizing radiation for ATM and DNA-PK
Reported limits
The full concentration series is not transcribed because Fig. 1E has an anomalous lane label. Replicate count and fitted EC50 uncertainty are not specified in these adopted locations. Vehicle composition is not specified.
Methods and source locations

Compound reported in the paper: Torin 2; Compound label in the paper: Torin2

Evidence concerns the reported experimental Torin2 material; supplier or lot equivalence is not established.

Materials and Methods: Immunoblot assays; Fig. 1E; Table 1; first Results subsection

ATM pathway: Chk2 phosphorylation: Concentration-dependent immunoblot assay; total Chk1/Chk2 and beta-actin controls shown in Fig. 1E — Fig. 1E; Table 1 ATM/ATR/DNAPK rows; first Results subsection

ATR pathway: Chk1 Ser317 phosphorylation: Concentration-dependent immunoblot assay; total Chk1/Chk2 and beta-actin controls shown in Fig. 1E — Fig. 1E; Table 1 ATM/ATR/DNAPK rows; first Results subsection

DNA-PK Ser2056 phosphorylation: Concentration-dependent immunoblot assay; total Chk1/Chk2 and beta-actin controls shown in Fig. 1E — Fig. 1E; Table 1 ATM/ATR/DNAPK rows; first Results subsection

In Vivo Studies

In a KRAS-driven mouse lung-tumor model, daily Torin2 monotherapy did not significantly inhibit tumor volume over four weeks. Combining Torin2 with the MEK inhibitor AZD6244 reduced tumor growth. Partial pathway recovery during prolonged monotherapy limits extrapolation from short-term target suppression. [1]

In an independent pancreatic-tumor mouse study, Torin 2 reduced tumor volume, and the Torin2–metformin combination also reduced tumor weight versus vehicle. High-dose Torin2 was reported toxic, with 3/10 animals surviving. Unequal attrition, including losses in controls, limits efficacy and tolerability comparisons. [2]

Single-agent and combination effects in KRAS-driven lung tumors

Animal study · Mice bearing genetically engineered KRAS G12D-driven lung tumors [1]

Over 4 weeks, neither Torin2 nor AZD6244 alone produced significant tumor-volume inhibition as reported by the authors, whereas their combination reduced tumor growth. Target suppression after short treatment partly recovered during prolonged monotherapy.

Conditions shared by the study groups

Frequency
Daily
Treatment course
4 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Torin2 alone
Torin2 40 mg/kg
Week-0 tumor-volume baseline; parallel AZD6244 and combination groups; vehicle tissue controls in immunohistochemistryNo significant tumor-volume inhibition reported; Fig. 5B n=4. Some recovery of pS6K and p4E-BP1 after 4 weeks relative to short treatment.[1]
AZD6244 alone
AZD6244 25 mg/kg
Week-0 baseline and parallel Torin2/combination groupsNo significant tumor-volume inhibition reported; Fig. 5B n=5.[1]
Torin2 + AZD6244
Torin2 40 mg/kg + AZD6244 25 mg/kg
Week-0 baseline and both single-agent groupsReduced tumor growth reported and visible in Fig. 5A,B; Fig. 5B n=4. This is a combination effect.[1]
Torin2 alone
Model: Mice bearing genetically engineered KRAS G12D-driven lung tumors
Vehicle: Torin2 suspended in saline
Reported limits: MRI bar error definition is not stated in the caption; exact volumes are not inferred. Route wording in retained manuscript is corrupted (“garage daily”); route is not normalized.
AZD6244 alone
Model: Mice bearing genetically engineered KRAS G12D-driven lung tumors
Vehicle: 0.5% methylcellulose and 0.4% polysorbate
Reported limits: No longitudinal vehicle MRI series shown in Fig. 5B. Route wording in retained manuscript is corrupted (“garage daily”); route is not normalized.
Torin2 + AZD6244
Model: Mice bearing genetically engineered KRAS G12D-driven lung tumors
Vehicle: Torin2: saline; AZD6244: 0.5% methylcellulose and 0.4% polysorbate
Reported limits: Exact effect size and statistical comparator are not reconstructed from the plot. Route wording in retained manuscript is corrupted (“garage daily”); route is not normalized.
Methods and source locations

Compound reported in the paper: Torin 2; Compound label in the paper: Torin2

Evidence concerns the reported experimental Torin2 material; supplier or lot equivalence is not established.

Results: Anti-tumor efficacy of combined Torin2/AZD6244 treatment in a KRAS-driven model of lung cancer; Fig. 5A–E; treatment and MRI methods

Torin2 alone · Fig. 5A–D and caption; efficacy Results; Mice cohort and drug treatment; MRI and PET/CT study

AZD6244 alone · Fig. 5A–D and caption; efficacy Results; Mice cohort and drug treatment; MRI and PET/CT study

Torin2 + AZD6244 · Fig. 5A–D and caption; efficacy Results; Mice cohort and drug treatment; MRI and PET/CT study

Pancreatic-tumor response and high-dose tolerability

Animal study · C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors [2]

After 12 days, all active-treatment groups had lower tumor volume than DMSO control in Table 1. Only the Torin2–metformin combination had a statistically significant tumor-weight reduction versus control. High-dose Torin2 was reported toxic, with only 3/10 mice surviving; attrition also affected control and other groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reported survival at study endpointSurvival, n=x/10 Control 5/10; Torin2 5 mg/kg 5/10; Torin2 25 mg/kg 3/10; metformin 10 mg/kg 6/10; combination 8/10[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
12 days
Vehicle
DMSO control; active-arm formulation not separately specified in the adopted text
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMSO controlDMSO vehicle groupReference group; substantial attrition even without active drug. Table 1 survival: 5/10.[2]
Low-dose Torin2
Torin2 5 mg/kg
DMSO vehicle groupTumor volume lower than control (Table 1 P<0.01); tumor-weight difference not significant. Table 1 survival: 5/10.[2]
High-dose Torin2
Torin2 25 mg/kg
DMSO vehicle groupTumor volume lower than control (Table 1 P<0.01); tumor weight P=0.08. Authors report toxicity. Table 1 survival: 3/10.[2]
Metformin alone
Metformin 10 mg/kg
DMSO vehicle groupTumor volume lower than control (Table 1 P<0.004); tumor-weight difference not significant. Table 1 survival: 6/10.[2]
Torin2 + metformin
Torin2 5 mg/kg + metformin 10 mg/kg
DMSO vehicle groupTumor volume (Table 1 P<0.0004) and tumor weight (P<0.002) lower than control. These control comparisons do not establish formal synergy or superiority to every single-agent group. Table 1 survival: 8/10.[2]
DMSO control
Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
Low-dose Torin2
Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
High-dose Torin2
Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
Metformin alone
Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
Torin2 + metformin
Model: C57BL/6 albino mice with orthotopic KPC-derived pancreatic tumors
Reported limits: Endpoint-specific n and all attrition causes/timing are unclear; do not interpret surviving-animal endpoint differences as an unqualified survival benefit.
Methods and source locations

Compound reported in the paper: Torin 2; Compound label in the paper: Torin2

Evidence concerns the reported experimental Torin2 material; supplier or lot equivalence is not established.

Methods: Reagents and orthotopic animal treatment; Results: tumor response; Table 1; Fig. 1 and caption

Reported survival at study endpoint: Counts as labeled in Table 1; not a Kaplan–Meier analysis — Table 1 Survival row; tumor response Results

DMSO control · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results

Low-dose Torin2 · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results

High-dose Torin2 · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results

Metformin alone · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results

Torin2 + metformin · Table 1 including footnote; Fig. 1/caption; orthotopic treatment Methods; tumor response Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1223001-51-1
Applications mTOR inhibitor
Formula C24H15F3N4O
Molecular Weight 432.4
SMILES
C1=CC(=CC(=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CN=C(C=C5)N)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 18 mg/mL (41.63 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1.4 mg/mL
Vehicle
5%DMSO+40%PEG300+5%Tween80+50%ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Liu Q, Xu C, Kirubakaran S, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR Cancer research (2013). PMID: 23436801 DOI: 10.1158/0008-5472.can-12-1702 Source material
  2. [2] Soliman GA, Shukla SK, Etekpo A, et al. The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth Current developments in nutrition (2020). PMID: 32908958 DOI: 10.1093/cdn/nzaa131 Source material

Publications

1 publication citing this product

  1. Diane Yang, .et al. , Diabetes, 2021, Oct;70(10):2419-2429 PMID: 34344789

Added to your cart

View Cart Checkout
Loading...